Enlivex Therapeutics Ltd. (TLV:ENLV)

Market Cap	846.29M
Revenue (ttm)	n/a
Net Income	-42.05M
EPS	-1.79
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	55,047
Average Volume	175,328
Open	361.70
Previous Close	361.70
Day's Range	330.00 - 361.70
52-Week Range	213.20 - 682.90
Beta	1.52
RSI	64.34
Earnings Date	Mar 30, 2026

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Country: Israel
• Stock Exchange: Tel Aviv Stock Exchange
• Ticker Symbol: ENLV

Financial Performance

Financial numbers in USD